title: Single-agent thalidomide induces response in T-cell lymphoma.
abstract: T-cell lymphoma is an aggressive lymphoma that cannot be cured despite aggressive therapy, including autologous stem cell transplantation. Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response.
authors.affiliation: Institut Paoli Calmettes Cancer Center, Marseille, France. damaj.gandhi@chu-amiens.fr
authors.forename: G
authors.initials: G
authors.lastname: Damaj
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: K
authors.initials: K
authors.lastname: Bilger
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide